C
DNA icon

Chescapmanager’s Ginkgo Bioworks DNA Stock Holding History

Chescapmanager’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,957
Closed -$508K – 40
2024
Q1 		$508K Hold
10,957
– – 0.05% 38
2023
Q4 		$741K Hold
10,957
– – 0.07% 37
2023
Q3 		$793K Hold
10,957
– – 0.1% 38
2023
Q2 		$815K Hold
10,957
– – 0.13% 37
2023
Q1 		$583K Buy
10,957
+1,250
+13% +$79.2K 0.09% 40
2022
Q4 		$656K Hold
9,707
– – 0.15% 33
2022
Q3 		$1.21M Sell
9,707
-6
-0.1% -$715 0.28% 36
2022
Q2 		$925K Sell
9,713
-15,375
-61% -$1.88M 0.22% 38
2022
Q1 		$4.04M Sell
25,088
-24,912
-50% -$4.85M 0.55% 38
2021
Q4 		$16.6M Hold
50,000
– – 2.22% 17
2021
Q3 		$23.2M Buy
+50,000
New +$24.3M 3.28% 7

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Chescapmanager's DNA Position: Q2 2024 in Review

Chescapmanager sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 10,957 shares — an estimated $508K sold.

Chescapmanager first reported a position in DNA in Q3 2021 and held it in 11 quarters. The position peaked at $23.2M in Q3 2021. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

  • Chescapmanager reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
  • Chescapmanager sold 10,957 Ginkgo Bioworks shares in Q2 2024, an estimated $508K.
  • Chescapmanager first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 11 quarters.
  • Chescapmanager's Ginkgo Bioworks position peaked at $23.2M in Q3 2021.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Chescapmanager's 13F filing for Q2 2024, filed 14 Aug 2024.